VS-105 is under clinical development by Vidasym and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect VS-105’s likelihood of approval (LoA) and phase transition for Chronic Kidney Disease (Chronic Renal Failure) took place on 13 Aug 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 13 Aug 2021 increased VS-105’s LoA and PTSR for Secondary Hyperparathyroidism.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their VS-105 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
VS-105 is under development for the treatment of osteoporosis, secondary hyperparathyroidism in chronic kidney disease, inflammatory bowel disease, psoriasis. It is administered through oral route. VS-105 acts by targeting vitamin D receptor.
It was under development for diabetic nephropathy, non-alcoholic steatohepatitis (NASH), non alcoholic fatty liver disease (NAFLD).
Vidasym operates in pharmaceutical and healthcare industry. It is headquartered in United States.
Quick View VS-105 LOA Data
|Highest Development Stage|